Open AccessO03 ‐ Expression of pulmonary surfactant protein D (SP‐D) and interleukin 13 in the serum of atopic and non‐atopic severe pediatric asthmatics: effects of glucocorticoid and sodium cromoglycate treatment
Author(s) -
GemouEngesaeth Vasiliki,
Laliotou Nikoletta,
Corrigan Chris J,
Chrousos George,
Haczku Angela
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s1-o3
Subject(s) - medicine , asthma , glucocorticoid , surfactant protein d , immunology , biomarker , allergy , gastroenterology , immune system , innate immune system , biochemistry , chemistry
Rationale Serum biomarker analysis is a valuable noninvasive tool for assessment of asthma severity in children. Surfactant protein D (SP-D) is an immunoprotective lung collectin produced in the lung in large quantities. We have previously shown that allergen-induced airway inflammation was associated with significant changes of SP-D release and that glucocorticoid therapy increases SP-D in the lung. Whether such changes could be detected in the peripheral circulation of asthmatic patients is not known. We hypothesized that serum SP-D would reflect disease severity in asthmatic children.